Compounds > isoursodeoxycholic acid
Page last updated: 2024-11-07

isoursodeoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isoursodeoxycholic acid: RN refers to (3beta,5beta,7beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isoursodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by beta-hydroxy groups at positions 3 and 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID127601
CHEMBL ID1233687
CHEBI ID43419
SCHEMBL ID209535
MeSH IDM0278325

Synonyms (42)

Synonym
CHEMBL1233687
iso-ursodeoxycholic acid
CHEBI:43419 ,
(3beta,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
78919-26-3
3beta,7beta-dihydroxy-5beta-cholanoic acid
3beta,7beta-dihydroxy-5beta-cholan-24-oic acid
LMST04010035
isoursodeoxycholic acid
C17662
3b,7b-dihydroxy-5b-cholan-24-oic acid
(4r)-4-[(3s,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid
unii-2r6lc4j3n9
2r6lc4j3n9 ,
cholan-24-oic acid, 3,7-dihydroxy-, (3beta,5beta,7beta)-
SCHEMBL209535
3|a-ursodeoxycholic acid
3b-ursodeoxycholic acid
mfcd25563270
3b,7b-dihydroxy-5b-cholanic acid
3b,7b-dihydroxy-5b-cholanate
3b,7b-dihydroxy-5b-cholanoic acid
3b-ursodeoxycholate
3b,7b-dihydroxy-5b-cholanoate
3b,7b-dihydroxy-5b-cholan-24-oate
(3beta,5beta,7alpha,14beta,17alpha)-3,7-dihydroxycholan-24-oic acid
3beta-ursodeoxycholic acid
CS-0062365
HY-113478
Q27104506
ES-2583
3beta-usrodeoxycholic acid
F82242
AKOS037652807
ursodeoxycholic acid impurity h [ep impurity]
3.beta.-ursodeoxycholic acid
cholan-24-oic acid, 3,7-dihydroxy-, (3.beta.,5.beta.,7.beta.)-
3.beta.,7.beta.-dihydroxy-5.beta.-cholanic acid
3.beta.,7.beta.-dihydroxy-5.beta.-cholan-24-oic acid
3.beta.,7.beta.-dihydroxy-5.beta.-cholanoic acid
DTXSID901318875
3 beta -ursodeoxycholic acid

Research Excerpts

Overview

Isoursodeoxycholic acid (isoUDCA) is a major metabolite of UDCA.

ExcerptReferenceRelevance
"Isoursodeoxycholic acid (isoUDCA) is a major metabolite of UDCA."( Human liver class I alcohol dehydrogenase gammagamma isozyme: the sole cytosolic 3beta-hydroxysteroid dehydrogenase of iso bile acids.
Höög, JO; Jörnvall, H; Marschall, HU; Nordling, E; Oppermann, UC; Persson, B; Svensson, S, 2000)		1.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxy-5beta-cholanic acidA hydroxy-5beta-cholanic acid carrying two hydroxy groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Drug induction of bile acid pathway025

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1165586Agonist activity at FXR (unknown origin) expressed in human HepG2 cells assessed as receptor transactivation at 10 uM incubated for 16 hrs by FXR response element driven HSP27-TK-luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
AID1165587Agonist activity at GP-BAR1 (unknown origin) in human HEK293 cells assessed as receptor transactivation at 10 uM incubated for 16 hrs by CRE-driven luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		2.110bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
ursodeoxycholic acid
Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		4.6661bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
muricholic acid
muricholic acid: internal standard in analysis of fecal bile acids; RN given refers to (3 alpha,5 beta)-isomer		2103alpha-hydroxy steroid;
6-hydroxy steroid;
7-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid
deoxycholic acid
Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.		2.2110bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
taurolithocholic acid
Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.		2.110bile acid taurine conjugate;
monocarboxylic acid amide		human metabolite
obeticholic acid
obeticholic acid: A farnesoid X receptor agonist and anticholestatic agent that is used in the treatment of chronic liver diseases; structure in first source.. obeticholic acid : A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis.		2.1103alpha-hydroxy steroid;
7alpha-hydroxy steroid;
dihydroxy-5beta-cholanic acid		farnesoid X receptor agonist;
hepatoprotective agent
bilirubin
[no description available]		3.3911biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Itching
[description not available]		02.110
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		02.110
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Bile Duct Obstruction
[description not available]		0210
Cholestasis
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).		0210
Biliary Cirrhosis
[description not available]		08.3911
Liver Cirrhosis, Biliary
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.		03.3911